295 related articles for article (PubMed ID: 28606339)
1. Introduction.
Chilton RJ
Am J Cardiol; 2017 Jul; 120(1S):S1-S3. PubMed ID: 28606339
[No Abstract] [Full Text] [Related]
2. Diabetic kidney disease in 2017: A new era in therapeutics for diabetic kidney disease.
Wanner C
Nat Rev Nephrol; 2018 Feb; 14(2):78-80. PubMed ID: 29307892
[No Abstract] [Full Text] [Related]
3. Dapagliflozin Cut Risk of Worsening Heart Failure.
Slomski A
JAMA; 2020 Jan; 323(4):301. PubMed ID: 31990313
[No Abstract] [Full Text] [Related]
4. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
Heerspink HJL; Kosiborod M; Inzucchi SE; Cherney DZI
Kidney Int; 2018 Jul; 94(1):26-39. PubMed ID: 29735306
[TBL] [Abstract][Full Text] [Related]
5. Reconceptualization of the Molecular Mechanism by Which Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Events.
Packer M
Circulation; 2019 Aug; 140(6):443-445. PubMed ID: 31381418
[No Abstract] [Full Text] [Related]
6. SGLT2 inhibitors in people with and without T2DM.
Khunti K
Nat Rev Endocrinol; 2021 Feb; 17(2):75-76. PubMed ID: 33293703
[No Abstract] [Full Text] [Related]
7. Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease.
Fitchett D; Inzucchi SE; Lachin JM; Wanner C; van de Borne P; Mattheus M; Johansen OE; Woerle HJ; Broedl UC; George JT; Zinman B;
J Am Coll Cardiol; 2018 Jan; 71(3):364-367. PubMed ID: 29348030
[No Abstract] [Full Text] [Related]
8. Introduction.
Chilton R
Am J Med; 2017 Jun; 130(6S):S1-S3. PubMed ID: 28526180
[No Abstract] [Full Text] [Related]
9. Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality.
Savarese G; Sattar N; Januzzi J; Verma S; Lund LH; Fitchett D; Zeller C; George JT; Brueckmann M; Ofstad AP; Inzucchi SE; Wanner C; Zinman B; Butler J
Circulation; 2019 Mar; 139(11):1458-1460. PubMed ID: 30855996
[No Abstract] [Full Text] [Related]
10. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF).
McMurray JJV; DeMets DL; Inzucchi SE; Køber L; Kosiborod MN; Langkilde AM; Martinez FA; Bengtsson O; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD;
Eur J Heart Fail; 2019 May; 21(5):665-675. PubMed ID: 30895697
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME.
Verma S; Mazer CD; Al-Omran M; Inzucchi SE; Fitchett D; Hehnke U; George JT; Zinman B
Circulation; 2018 Jan; 137(4):405-407. PubMed ID: 29133602
[No Abstract] [Full Text] [Related]
12. SGLT-2 inhibitors in diabetes: a focus on renoprotection.
Gonzalez DE; Foresto RD; Ribeiro AB
Rev Assoc Med Bras (1992); 2020 Jan; 66Suppl 1(Suppl 1):s17-s24. PubMed ID: 31939531
[TBL] [Abstract][Full Text] [Related]
13. An Exploratory Study of Dapagliflozin for the Attenuation of Albuminuria in Patients with Heart Failure and Type 2 Diabetes Mellitus (DAPPER).
Yoshihara F; Imazu M; Hamasaki T; Anzai T; Yasuda S; Ito S; Yamamoto H; Hashimura K; Yasumura Y; Mori K; Watanabe M; Asakura M; Kitakaze M;
Cardiovasc Drugs Ther; 2018 Apr; 32(2):183-190. PubMed ID: 29589153
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis of Dedicated Renal Outcome Trials Assessing the Cardio-renal Efficacy of Sodium-Glucose Co-transporter-2 Inhibitors in Patients With Chronic Kidney Disease and Albuminuria.
Patoulias D; Papadopoulos C; Stavropoulos K; Imprialos K; Doumas M
Am J Cardiol; 2021 Jan; 138():116-118. PubMed ID: 33045203
[No Abstract] [Full Text] [Related]
15. [Not Available].
Lanthier L; Dussault C; Huard G; Plourde MÉ; Cauchon M
Rev Med Interne; 2020 Feb; 41(2):143-144. PubMed ID: 31928796
[No Abstract] [Full Text] [Related]
16. EMPA-REG: Glucose excretion and lipid mobilization - not storage - saves lives.
Jørgensen NB; Pedersen J; Vaag AA
J Diabetes Complications; 2016; 30(4):753. PubMed ID: 26970674
[No Abstract] [Full Text] [Related]
17. Dapagliflozin (Farxiga) - a new indication for heart failure.
Med Lett Drugs Ther; 2020 Jun; 62(1601):102-103. PubMed ID: 32724023
[No Abstract] [Full Text] [Related]
18. SGLT2 inhibitors for primary prevention of cardiovascular events.
Raz I; Cernea S; Cahn A
J Diabetes; 2020 Jan; 12(1):5-7. PubMed ID: 31755238
[No Abstract] [Full Text] [Related]
19. Reduced hospitalization for heart failure using anti-diabetic drug dapagliflozin: implications of DECLARE-TIMI 58 for the basic science community.
Kondo H; Takahashi N
Cardiovasc Res; 2019 May; 115(6):e54-e57. PubMed ID: 31077584
[No Abstract] [Full Text] [Related]
20. Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control.
Inzucchi SE; Kosiborod M; Fitchett D; Wanner C; Hehnke U; Kaspers S; George JT; Zinman B
Circulation; 2018 Oct; 138(17):1904-1907. PubMed ID: 30354665
[No Abstract] [Full Text] [Related]
[Next] [New Search]
